Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 593-skin-ulcers-with-cc
    Ask Trek AI about this page

    Skin Ulcers with CC: Inpatient Reimbursement Overview

    DRG 593 covers inpatient care for skin ulcers when a Complication or Comorbidity is present, including pressure injuries and lower-extremity ulcers with associated medical conditions. Correct classification into this Diagnosis-Related Group influences inpatient reimbursement by reflecting higher expected resource needs and complexity for the Centers for Medicare & Medicaid Services payment framework.

    Customize your policy alerts

    Sign up for drg 593 policy alerts

    Get alerted when payer policies referencing 593 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 593 Overview

    DRG 593 covers inpatient admissions primarily for treatment of skin ulcers when a Complication or Comorbidity is present, encompassing pressure injuries, venous stasis ulcers, arterial ulcers, and diabetic foot ulcers with associated comorbid conditions. This Diagnosis-Related Group groups cases with increased resource use due to factors such as infection, poor wound healing, or significant medical comorbidity. It matters for Medicare payment because classification into this Diagnosis-Related Group affects reimbursement levels tied to expected resource consumption and length of stay. Accurate coding of the ulcer type and accompanying Complication or Comorbidity is therefore central to appropriate Medicare Severity Diagnosis-Related Group assignment.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute wound care intervention trials investigating advanced dressing materials, topical biologics, or adjunctive therapies (e.g., negative pressure wound therapy) for hospitalized patients with complicated skin ulcers and a documented comorbidity that qualifies as a CC. These studies enroll inpatients with moderate-to-severe pressure injuries, venous or arterial ulcers with infection or delayed healing, often stratified by comorbidity burden (diabetes, peripheral vascular disease) to assess time to wound closure and infection control. Such research is directly relevant to providers and payers because improved acute interventions can shorten length of stay, reduce need for surgical debridement, and lower inpatient resource utilization and readmission risk.
    • Comparative effectiveness studies evaluating surgical versus conservative management pathways for skin ulcers complicated by cellulitis or exposed soft tissue, including patient-centered outcomes and cost-effectiveness analyses. These trials focus on adult inpatients who meet DRG criteria due to coexisting complications, comparing outcomes such as healing rates, complication frequency, functional status, and total episode-of-care costs across different procedural approaches and perioperative protocols. Results inform clinical decision-making on optimal timing of operative debridement, antibiotic strategies, and resource allocation, helping payers and hospital leaders develop pathways that balance clinical benefit with reimbursement and utilization constraints.
    • Post-discharge outcomes and care-transition studies assessing multidisciplinary outpatient follow-up models, home health interventions, and remote wound monitoring for patients discharged after an inpatient stay for skin ulcers with CCs. These prospective cohort or pragmatic trial designs enroll patients at discharge—often older adults with multimorbidity—and measure readmission rates, wound recurrence, patient adherence, and downstream costs over 30–180 days. Evidence from these studies guides providers and payers in designing discharge planning, home-care authorizations, and bundling approaches to reduce avoidable rehospitalizations and improve long-term healing and functional outcomes.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    571-SKIN-DEBRIDEMENT-WITH-CC

    Skin Debridement with CC: Inpatient Reimbursement Overview

    572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    577-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.